

Balaxi Pharmaceuticals Limited

Date: 10th July, 2026

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Subject: Reconciliation of Share Capital Audit Report for the quarter ended 30th June, 2026

Dear Sir / Madam,

In terms of Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018, we are enclosing herewith the Reconciliation of Share Capital Audit Report for the quarter ended 30th June, 2026, issued by M/s. BVR & Associates Company Secretaries LLP (LLPIN: AAE – 7079), Practicing Company Secretaries.

The same will also be available on the Company's website at www.balaxipharma.in

This is for your information and record.

Thanking You.

Yours faithfully,
For Balaxi Pharmaceuticals Limited

Aman Purohit
(Company Secretary & Compliance Officer)
ICSI Membership No.: A59345

(Encl: As above)

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

To,
Balaxi Pharmaceuticals Limited
Plot No.409, H. No. 8-2-293,
Maps Towers, 3rd Floor, Phase-III,
Road No.81, Jubilee Hills,
Hyderabad, Telangana - 500096, India

Dear Sir/ Madam,

We have examined the relevant books, registers, forms, documents and papers produced electronically before us by **M/s. Balaxi Pharmaceuticals Limited** ('the Company') and its Registrars and Transfer Agent (RTA), M/s. Aarthi Consultants Private Limited, in respect of Reconciliation of Share Capital Audit as per Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. To the best of our knowledge and according to the information and explanations given to us, we certify the following:

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

1	For Quarter Ended	June 30, 2026
2	ISIN	INE618N01022
3	Face Value	Rs. 2/- per equity share
4	Name of the Company	Balaxi Pharmaceuticals Limited
5	Registered Office Address	Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad - 500096, Telangana, India.
6	Correspondence Address	Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad - 500096, Telangana, India
7	Telephone & Fax Nos.	+ 91 40 2355 5300
8	Email address	secretarial@balaxi.in

Corporate Office: : Kousthubham, # 33/1797, Manakodam Rd, Perandoor, Elamakkara, Kochi - 682 026
Ph : +91 98956 32786, E-mail: yogi@directus.co.in

Registered Office: Swastika, First Floor, Chitteth House, P C Road, Vytilla P.O., Cochin - 682 019
Ph: +91 98956 31786, E-mail : balu@directus.co.in

9	Names of the Stock Exchanges where the company's securities are listed:	National Stock Exchange of India Limited (NSE)	
		Number of shares	% of Total Issued Cap.
10	Issued Capital	5,52,07,500	100%
11	Listed Capital (Exchange wise) (as per company records) National Stock Exchange of India Limited (NSE)	5,52,07,500	100%
12	Held in dematerialised form in CDSL	4,55,86,809	82.57358%
13	Held in dematerialised form in NSDL	94,70,081	17.15361%
14	Physical	1,50,610	0.27281%
15	Total No. of shares (12+13+14)	5,52,07,500	100%
16	Reasons for difference if any, between	N.A	

17. Certifying the details of changes in share capital during the quarter under consideration as per Table below:

Particulars***	No. of shares	Applied / Not Applied/ for listing	Listed on Stock Exchanges	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. appr. pending for SE
NIL	NA	NA	NA	NA	NA	NA

*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, Any other (to specify).

18	Register of Members is updated (Yes / No)	Yes
19	Reference of previous quarter with regards to excess dematerialized shares, if any.	NIL

Yojindunass



20	Has the company resolved the matter mentioned in point no. 19 above in the current quarter? If not, reason why?	Not Applicable
----	---	----------------

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
Confirmed after 21 Days	NIL	NIL	NA
Pending for more than 21 days	NIL	NIL	NA

22	Name, Telephone & Fax No. of the Compliance Officer of the Company.	Mr. Aman Purohit Telephone No.: + 91 40 2355 5300 Email: secretarial@balaxi.in
23	Name, Address, Tel. & Fax No., Regn. no. of the Practicing Company Secretary certifying the report	CS. Yogindunath S BVR & Associates Company Secretaries LLP, "Kousthubham", Door No. 33/1797, Manakodam Road, Perandoor, Elamakkara, Kochi - 682026 Contact No.: +91 98956 32786 Membership No.: 7865 Certificate of Practice No.: 9137 Peer Review No.: P2010KE020500



24	Appointment of common agency for share registry work (if yes, name and address)	Aarthi Consultants Private Limited 1-2-285, Domalguda, Hyderabad-500029 Ph: 040 -2763 8111, 040 - 2763 4445 Fax: (91-40) 2763 2184
25	Any other detail that the Company Secretary may like to provide. (e.g. BIFR company, delisting from SE,	Nil

YOGINDUNATH. S.
Designated Partner
BVR & Associates Company Secretaries LLP
"Kousthubham", Door No: 33/1797
Manakodam, Rd., Perandoor, Elamakkara
Kochi-682 026, Kerala.
CP No: 9137, FCS 7865, LLP IN AAE-7079

Yogindunath S

CS Yogindunath S
BVR & Associates Company Secretaries LLP,
Practicing Company Secretaries

M NO: 7865

CP: 9137

Peer Review No: P2010KE020500

UDIN: F007865H000778448



Date: 08/07/2026

Place: Cochin